INDIUM-111 BLEOMYCIN TUMOR SCANNING IN LYMPHOMA
INDIUM-111 BLEOMYCIN TUMOR SCANNING IN LYMPHOMA
复制标题
DOI：
10.1002/mpo.2950010104
复制
发表时间：
1975-01-01
期刊：
影响因子：
--
通讯作者：
SALMON S E
中科院分区：
文献类型：
--
作者：
JONES S E;LILIEN D L;SALMON S E
一种新的放射性药物，铟- 111标记的博来霉素（IB），在55例淋巴瘤患者中作为肿瘤显像剂进行了评估。在静脉给药后48小时进行的75次全身扫描中，79%的人正确识别了总体疾病活动。19名患者的连续扫描准确反映了他们疾病状态的变化。横膈膜上下的淋巴和软组织受累部位最容易通过扫描确定。骨髓和肝脏受累较难检测，因为所考虑的器官组织背景正常。5例患者表现为弥漫性肺摄取IB，仅有1例得到解释。为了确定IB扫描的准确性，我们评估了731个潜在肿瘤累及的单独部位，结果为：真阳性90%，假阴性10%，假阳性4%，真阴性96%。因此，用铟- 111博莱霉素进行肿瘤扫描是淋巴瘤患者初始分期和系列评估的重要新技术。
A new radiopharmaceutical, indium‐111 labeled bleomycin (IB), was evaluated as a tumor‐imaging agent in 55 patients with lymphoma. Overall disease activity was correctly identified in 79% of 75 whole‐body scans obtained 48 hours after intravenous administration of IB. Serial scans in 19 patients accurately reflected changes in their disease status. Lymphatic and soft tissue sites of involvement both above and below the diaphragm were most readily identified by scanning. Bone marrow and hepatic involvements were more difficult to detect because of normal tissue background in the considered organs. Five patients manifested diffuse pulmonary uptake of IB and only in one case was it explained.To determine the accuracy of scanning with IB, we evaluated 731 individual sites of potential tumor involvement with these results: true positives 90%, false negatives 10%, false positives 4%, and true negatives 96%. Thus, tumor scanning with indium‐111 bleomycin is an important new technique for the initial staging and serial evaluation of patients with lymphoma.